Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Sionna Therapeutics is a biopharmaceutical company focused on developing novel medicines to treat cystic fibrosis by stabilizing the CFTR protein's NBD1 domain. Its pipeline includes small molecule stabilizers and combination therapies aimed at restoring CFTR function, especially for patients with the F508del mutation. The company leverages advanced preclinical models and clinical trials to deliver targeted treatments that address unmet needs in CF care.
This description was generated via AI from an annual report. Updated about 1 year ago.